Market Overview

Horizon Therapeutics Has 'Headroom For Value Creation,' BMO Says In Upgrade

Horizon Therapeutics Has 'Headroom For Value Creation,' BMO Says In Upgrade

Horizon Therapeutics PLC (NASDAQ: HZNP), an actively traded small-cap biotech, is poised for further upside in the near-term on its product strength, according to BMO Capital Markets.

The Analyst

Gary Nachman upgraded Horizon Therapeutics from Market Perform to Outperform and lifted the price target from $29 to $36. 

The Thesis

Horizon's Krystexxa, indicated to treat gout, catalyzed a strong second quarter for the company and is likely to be a bigger source of upside going forward, Nachman said in a Tuesday upgrade note. (See his track record here.) 

The drug fetched sales of $13 million by virtue of its more than 20% growth, significantly exceeding expectations, the analyst said. The strong showing came despite expectations that growth would slow, especially due to 340B, a federal government drug discount program, he said. 

Nachman expressed confidence in Krystexxa's increasing penetration in the chronic gout market.

Tepro, which is being evaluated for thyroid eye disease, or TED, is a significant product in development and makes the stock worth owning as the company approaches the approval and launch of the drug in the first half of 2020, the analyst said. 

"With HZNP's considerable commercial preparation for Tepro and history of executing well commercially, we see good risk/reward into that launch." 

Horizon represents a scarcity value in specialty pharma, Nachman said. 

"With successful evolution of business model to higher-value orphan drug opportunities while also substantially improving capital structure (leverage now 1.1x), we see a lot more headroom for value creation and believe a premium for the stock is warranted." 

The Price Action

Horizon shares were up 1.89% at $27.06 at the time of publication Wednesday. 

Related Links:

The Daily Biotech Pulse: Regeneron's Bad Cholesterol Drug Aces Late-Stage Trial, Oncolytics Offering

Lilly's Psoriasis Drug Found Superior To J&J's Tremfya In Phase 4 Study

Photo courtesy of Horizon Therapeutics. 

Latest Ratings for HZNP

Jan 2020Initiates Coverage OnNeutral
Dec 2019MaintainsBuy
Dec 2019MaintainsOutperform

View More Analyst Ratings for HZNP
View the Latest Analyst Ratings

Posted-In: BMO Capital Markets Gary NachmanAnalyst Color Biotech Upgrades Price Target Analyst Ratings General Best of Benzinga


Related Articles (HZNP)

View Comments and Join the Discussion!

Latest Ratings

HIICowen & Co.Downgrades
EIGRLadenburg ThalmannMaintains31.0
ZIONB of A SecuritiesDowngrades
ESJanney CapitalDowngrades
ARNCLongbow ResearchDowngrades
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at